EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders

Patricia Lam, Julia Newland, Richard L M Faull iD, Andrea Kwakowsky iD

Molecules · 2023

DOI: 10.3390/molecules28031344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2023. Verfasst von Patricia Lam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, …. Hauptthemen laut MEDLINE: Epilepsy, Symporters. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer’s New Zealand, Freemasons New Zealand, Alzheimer’s New Zealand Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurological diseases including Alzheimer’s, Huntington’s disease, Parkinson’s disease, Down syndrome and epilepsy, and neuropsychiatric disorders such as schizophrenia, are conditions that affect not only individuals but societies on a global scale. Current therapies offer a means for small symptomatic relief, but recently there has been increasing demand for therapeutic alternatives. The γ-aminobutyric acid (GABA)ergic signaling system has been investigated for developing new therapies as it has been noted that any dysfunction or changes to this system can contribute to disease progression. Expression of the K-Cl-2 (KCC2) and N-K-C1-1 (NKCC1) cation-chloride cotransporters (CCCs) has recently been linked to the disruption of GABAergic activity by affecting the polarity of GABAA receptor signaling. KCC2 and NKCC1 play a part in multiple neurological and neuropsychiatric disorders, making them a target of interest for potential therapies. This review explores current research suggesting the pathophysiological role and therapeutic importance of KCC2 and NKCC1 in neuropsychiatric and neurological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsySymportersHumansCationsChloridesSolute Carrier Family 12, Member 2K Cl- Cotransporters

Stichwörter der Autor:innen

Alzheimer’s diseaseDown syndromeGABAHuntington’s diseaseKCC2NKCC1Parkinson’s diseaseepilepsyneurodevelopmentneuropsychiatricschizophrenia

Substanzen

CationsChloridesSolute Carrier Family 12, Member 2SymportersSLC12A5 protein, humanK Cl- CotransportersSLC12A2 protein, human

Autor:innen und Institutionen

  • Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
  • Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, University of Galway, H91 W5P7 Galway, Ireland.

ORCID-Profile: Richard L M Faull, Andrea Kwakowsky

Förderung

  • Alzheimer’s New Zealand
  • Freemasons New Zealand
  • Alzheimer’s New Zealand Charitable Trust
  • Health Research Council of New Zealand

Zitieren

APA

Lam, P., Newland, J., Faull, R. L. M., & Kwakowsky, A. (2023). Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders. Molecules. https://doi.org/10.3390/molecules28031344

Vancouver

Lam P, Newland J, Faull RLM, Kwakowsky A. Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders. Molecules. 2023. doi:10.3390/molecules28031344

BibTeX
@article{Lam2023,
  author = {Lam, Patricia and Newland, Julia and Faull, Richard L M and Kwakowsky, Andrea},
  title = {Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28031344}
}
Kostenlos starten →